Abbott Laboratories (ABT)
(Real Time Quote from BATS)
$103.55 USD
+0.34 (0.33%)
Updated May 21, 2024 10:07 AM ET
3-Hold of 5 3
C Value C Growth B Momentum C VGM
Brokerage Reports
Abbott Laboratories [ABT]
Reports for Purchase
Showing records 481 - 500 ( 525 total )
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
The Chinese Pharmaceutical Industry: Fortnightly Update
Provider: RODMAN & RENSHAW, CO.
Analyst: PIROS E
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Emerging markets strategy to become a more important growth driver in near to medium term
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
4Q Sales Boosted by 23% Pharmaceuticals Growth. EPS Grew at a Double-Digit Rate.
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Trimming Our 2011 Projections to Consensus Levels
Provider: WEDBUSH SECURITIES INC.
Analyst: NALBONE P
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Number of late-stage projects in the Pharma pipeline to boost longer term growth.
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Sales A Tad Light - High-Quality EPS Beat - Best Gross Margin in At Least a Decade
Provider: WEDBUSH SECURITIES INC.
Analyst: NALBONE P
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Third Quarter EPS Exceeded Expectations. Sales Were a Little Light.
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Third Quarter EPS Exceeded Expectations. Sales Were a Little Light
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Med Tech September Quarter Preview: Stagnation for Most Large Device Markets
Provider: WEDBUSH SECURITIES INC.
Analyst: NALBONE P
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
A Very Busy Week -Beetles and Bardoxolone, Integrating Solvay, SPIRIT IV at Two Years and More to ABSORB
Provider: WEDBUSH SECURITIES INC.
Analyst: NALBONE P
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Likely approval of Bioresorbable stent to further strengthen long term growth prospects.
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
FDA Panel Meets Wednesday to Decide Fate of Obesity Drug Meridia - Potential for More Negative Headlines, But No Material Damage to ABT Even if Drug Pulled From Market
Provider: WEDBUSH SECURITIES INC.
Analyst: NALBONE P
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
This House Is Still Standing Stronger than Ever as Most of the Neighborhood Falls Down Around it - the Big Cap Health Care Product Name to Buy Now
Provider: WEDBUSH SECURITIES INC.
Analyst: NALBONE P